Teduglutide is in clinical development for infants aged four to twelve months with short bowel syndrome (SBS) who are dependent on parenteral support (PS). SBS is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Consequently, individuals with SBS often have a reduced ability to absorb nutrients such as fats, carbohydrates (sugars) vitamins, minerals, trace elements and fluids. Although SBS in infants is a very rare condition, SBS can incur significant illness including intestinal failure, cholestasis, sepsis, and death. However, there is a lack of approved treatments for infants with SBS.
Teduglutide for short bowel syndrome in infants
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Partners-Industry_Motifs_Motifs_Conduction-broadcasting_RGB-scaled_edited_1233.jpg)
Teduglutide is in clinical development for infants aged four to twelve months with short bowel syndrome (SBS) who are dependent on parenteral support (PS). SBS is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine.
Interventions:
Teduglutide
Indications:
Short bowel syndrome
Therapeutic Areas:
Gastroenterology
Year:
2022